Track AstraZeneca PLC — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

AstraZeneca PLC AZN · Stock Open AstraZeneca PLC in new tab

184.45 USD
P/E
26.09
EPS
7.07
Yield
1.70%
Safety Score
92
P/B
5.53
ROE
22.57
Beta
0.16
Target Price
208.08 USD
AstraZeneca PLC logo

AstraZeneca PLC

🧾 Earnings Recap – Q3 2026

AstraZeneca’s shares rose 7.0% after earnings, with investors responding to 7% revenue growth, 14% core EPS growth and a pipeline update that added more than $10 billion in non-risk-adjusted peak-sales potential. Growth was broad across key therapy areas, though Farxiga and Brilinta exclusivity losses and volume-based procurement in China remained headwinds.

  • For the first nine months, total revenue grew 7% and core EPS increased 14%; revenue growth was 12% excluding Farxiga and Brilinta.
  • Oncology, rare disease and respiratory & immunology delivered double-digit growth, more than offsetting expected headwinds from Farxiga and Brilinta losses of exclusivity and CVRM.
  • China growth was affected by volume-based procurement; excluding that impact, revenue grew 13%, with growth across all therapy areas.
  • The company reported positive results from 12 Phase III programs since February and first approvals for four new medicines, bringing approved new molecular entities to 14.
  • Management cited more than $10 billion in non-risk-adjusted peak-year sales potential from positive pipeline readouts, while emphasizing continued investment toward its $80 billion revenue ambition for 2030.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 9, 2027
P/E26.09
EPS7.07
Book Value33.35
Price to Book5.53
Debt/Equity66.25
% Insiders0.317%
Growth
Revenue Growth0.07%
Earnings Growth0.24%
Estimates
Forward P/E16.30
Forward EPS11.32
Target Mean Price208.08
Dividend
Dividend Yield1.70%
Annual dividends3.22 USD
Ex-Div. DateAug. 7, 2026
Payout45.08%
5y avg Yield2.28%

DCF valuation

Model fair value for AstraZeneca PLC (AZN)
Result
Sign in to run the valuation for AZN.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
12 analysts · consensus Buy · mean target 208.08 USD (low 158.00, high 240.00) · as of 15 Nov 2026
Low 158.00
Mean 208.08
High 240.00
Price 184.45
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

AstraZeneca PLC Logo AstraZeneca PLC Analysis (AZN)

United Kingdom Health Care Official Website Stock

Is AstraZeneca PLC a good investment? AstraZeneca PLC (AZN) is currently trading at 184.45 USD. Market analysts have a consensus price target of 208.08 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 26.09. This valuation is generally in line with the broader market.

Earnings Schedule: AstraZeneca PLC is expected to release its next earnings report on Feb. 9, 2027. The market consensus estimate for Forward EPS is 11.32.

For income investors, AstraZeneca PLC pays a dividend yield of 1.70%. With a payout ratio of 45%, the dividend appears sustainable.

Investor FAQ

Does AstraZeneca PLC pay a dividend?

Yes, it pays an annual dividend of 3.22 USD (1.70% yield).

What asset class is AstraZeneca PLC?

AstraZeneca PLC is classified as a Stock. You can compare it against 17 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 9, 2027. The company currently has a trailing EPS of 7.07.

Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies for rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, USA, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of oral candidates; Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates; and Carterra, Inc. to advances lab-in-the-loop drug discovery through new scientific research collaboration. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is based in Cambridge, the United Kingdom.

Exchange Ticker
MEX (Mexico) AZNN.MX
BUE (Argentina) AZN.BA
GER (Germany) ZEG.DE
MIL (Italy) UV4L0Q.MI
BER (Germany) ZEG.BE
DUS (Germany) ZEG.DU
HAN (Germany) ZEG.HA
FRA (Germany) ZEGA.F
STU (Germany) ZEGA.SG
FRA (Germany) ZEG.F
HAM (Germany) ZEG.HM
MUN (Germany) ZEG.MU
STU (Germany) ZEG.SG
NMS (United States) AZN
PNK (United States) AZNCF
LSE (United Kingdom) AZN.L
STO (Sweden) AZN.ST
Trades
Dividend Yield
1.70%
5y avg 2.28%
Annual Dividends
3.22USD
Next Ex. Div Date
Aug. 7, 2026
Payout Ratio
45.08%
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2027
3.29 USD
Sept. 13, 2027 (estimated) 1.0018
March 19, 2027 (estimated) 2.2892
▸2026
3.23 USD
Sept. 8, 2026 1.0600
March 23, 2026 2.1719
▸2025
1.57 USD
Sept. 8, 2025 0.5150
March 24, 2025 1.0500
▸2024
1.48 USD
Sept. 9, 2024 0.5000
March 25, 2024 0.9850
▸2023
3.40 USD
Sept. 11, 2023 0.4650
March 27, 2023 0.9650
March 27, 2023 1.9700
▸2022
4.32 USD
Sept. 12, 2022 0.4550
Sept. 12, 2022 0.9300
March 28, 2022 0.9650
March 28, 2022 1.9700
▸2021
2.29 USD
Sept. 13, 2021 0.4400
Sept. 13, 2021 0.9000
March 29, 2021 0.9500
▸2020
2.29 USD
Sept. 14, 2020 0.4400
Sept. 14, 2020 0.9000
March 30, 2020 0.9500
▸2019
1.40 USD
Sept. 9, 2019 0.4500
March 27, 2019 0.9500
▸2018
1.40 USD
Sept. 10, 2018 0.4500
March 19, 2018 0.9500
▸2017
1.40 USD
Sept. 11, 2017 0.4500
March 20, 2017 0.9500
▸2016
1.40 USD
Sept. 12, 2016 0.4500
March 21, 2016 0.9500
▸2015
2.35 USD
Sept. 14, 2015 0.4500
March 23, 2015 1.9000
▸2014
2.80 USD
Sept. 15, 2014 0.9000
March 24, 2014 1.9000
▸2013
2.80 USD
Sept. 16, 2013 0.9000
March 18, 2013 1.9000
▸2012
2.85 USD
Sept. 10, 2012 0.9000
March 19, 2012 1.9500
▸2011
2.70 USD
Sept. 12, 2011 0.8500
March 14, 2011 1.8500
▸2010
2.41 USD
Sept. 13, 2010 0.7000
March 15, 2010 1.7100
▸2009
2.09 USD
Sept. 14, 2009 0.5900
March 16, 2009 1.5000
▸2008
1.90 USD
Sept. 15, 2008 0.5500
March 17, 2008 1.3500
▸2007
1.75 USD
Sept. 17, 2007 0.5200
March 19, 2007 1.2300
▸2006
1.41 USD
Sept. 18, 2006 0.4900
March 20, 2006 0.9200
▸2005
1.03 USD
Sept. 19, 2005 0.3800
March 21, 2005 0.6450
▸2004
0.84 USD
Sept. 20, 2004 0.2950
April 6, 2004 0.5400
▸2003
0.78 USD
Oct. 6, 2003 0.2550
April 7, 2003 0.5222
▸2002
0.78 USD
Oct. 7, 2002 0.2556
April 8, 2002 0.5222
▸2001
0.78 USD
Oct. 5, 2001 0.2555
April 9, 2001 0.5222
▸2000
1.85 USD
Nov. 14, 2000 1.0730
Oct. 23, 2000 0.2555
April 17, 2000 0.5222
▸1999
0.75 USD
Oct. 25, 1999 0.2555
April 28, 1999 0.4956
▸1998
2.33 USD
Sept. 16, 1998 0.2830
March 18, 1998 1.5360
March 18, 1998 0.5120
▸1997
2.85 USD
Sept. 17, 1997 0.7990
Sept. 17, 1997 0.2663
March 19, 1997 1.3420
March 19, 1997 0.4473
▸1996
1.98 USD
Sept. 20, 1996 0.7220
Sept. 20, 1996 0.2407
March 22, 1996 0.7600
March 22, 1996 0.2533
▸1995
2.30 USD
Sept. 22, 1995 0.6710
Sept. 22, 1995 0.2237
March 24, 1995 1.0520
March 24, 1995 0.3507
▸1994
2.08 USD
Sept. 23, 1994 0.6160
Sept. 23, 1994 0.2053
March 18, 1994 0.9430
March 18, 1994 0.3143
▸1993
0.77 USD
Sept. 24, 1993 0.5790
Sept. 24, 1993 0.1930
Upcoming Dividends
Name Payment Date Status Amount
AstraZeneca PLC Sep 08, 2026 1.06 USD
AstraZeneca PLC Mar 23, 2026 2.17191 USD
Stock Splits
Split Date Split Ratio to 1
April 8, 1998 3:1
July 27, 2015 2:1
Feb. 2, 2026 1:2
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion